U.S. FDA Declines to Authorize Verrica's Viral Skin Disease Treatment

Reuters2022-05-25

(Reuters) - The U.S. Food and Drug Administration (FDA) declined to approve Verrica Pharmaceuticals Inc's drug for the treatment of a viral skin disease known as molluscum contagiosum, the company said on Tuesday.

The disease is caused by a pox virus and leads to skin-toned to pink-colored lesions that can cause pain, inflammation, itching and bacterial infection. While the lesions usually go away within a year without scarring, some cases could take a lot more time.

There are currently no approved treatments in the United States for the condition.

The FDA denied approval for Verrica's drug VP-102 due to deficiencies identified at Sterling Pharmaceuticals Services, a contract manufacturer that produces Verrica's bulk solution drug product, during a general re-inspection, which resulted in an Official Action Indicated (OAI) status.

An OAI is the FDA's most serious category of violation, and regulatory experts say it could lead to a prohibition on the sale of drugs from a facility if not addressed.

Verrica said it had been told that internal policy is preventing the health regulator from "communicating the label and approving the NDA (New Drug Application)" when a contract manufacturer is placed on OAI status.

None of the issues identified by the FDA during its re-inspection were specific to the manufacturing of VP-102, Verrica said in its statement.

The health regulator had declined Verrica's marketing application for the drug last year, citing general quality issues at one of the company's third-party manufacturing facilities.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Leave a comment
4